Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Pure Biologics S.A.
Modality
UNKNOWN
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06700070CT.gov A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Soft Tissue Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pba-0111 (this asset) | Pure Biologics S.A. | Early P1 | C · 39 |
| Palbociclib | Brown University | P2 | BB |
| Nivestim | University of California, Irvine | P3 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | BB |
| Adriamycin | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P3 | BB |
| Dacarbazine | Institut Bergonié | P3 | BB |
| Irinotecan | GI Innovation, Inc. | P1/2 | BB |
| Tislelizumab | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BB |
| Olaparib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Soft Tissue Sarcoma cohort
Other indications for Pba-0111
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Head And Neck Squamous Cell Carcinoma | — | Early P1 | C · 34 |
| Triple-Negative Breast Carcinoma | — | Early P1 | C · 34 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pba-0111 in Soft Tissue Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pba-0111-soft-tissue-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →